Jianchang Lin

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Philippe Moreau, Tamás Masszi, Norbert Grząśko et al. · New England Journal of Medicine · 2016 · 1K citations · Full text

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With <i>EGFR</i> Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer

Caicun Zhou, Suresh S. Ramalingam, Tae Min Kim et al. · JAMA Oncology · 2021 · 282 citations · Full text

Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with <i>EGFR</i> Exon 20 Insertion Mutations from a Phase I/II Trial

Gregory J. Riely, Joel W. Neal, D. Ross Camidge et al. · Cancer Discovery · 2021 · 219 citations · Full text

Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients

Hervé Avet‐Loiseau, Nizar J. Bahlis, Wee Joo Chng et al. · Blood · 2017 · 111 citations · Full text

Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537)

Philippe Moreau, Tamás Masszi, Norbert Grząśko et al. · Blood · 2015 · 66 citations